BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 8862260)

  • 1. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
    Sampaio EP; Malta AM; Sarno EN; Kaplan G
    Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):268-73. PubMed ID: 8862260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for erythema nodosum leprosum.
    Manandhar R; LeMaster JW; Roche PW
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
    Feuth M; Brandsma JW; Faber WR; Bhattarai B; Feuth T; Anderson AM
    Lepr Rev; 2008 Sep; 79(3):254-69. PubMed ID: 19009975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pattern of bacillary clearance in multibacillary leprosy patients with multidrug therapy.
    Kumar A; Girdhar A; Girdhar BK
    Acta Leprol; 2003; 12(3):123-8. PubMed ID: 15040703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Histoid leprosy with erythema nodosum leprosum].
    Alioua Z; Sbai M; Elhaouri M; Bouzidi A; Boudi O; Ghfir M; Benomar S; Sedrati OL
    Acta Leprol; 2003; 12(3):107-11. PubMed ID: 15040700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
    de Carsalade GY; Achirafi A; Flageul B
    Acta Leprol; 2003; 12(3):117-22. PubMed ID: 15040702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous leprosy.
    Rea TH
    Int J Lepr Other Mycobact Dis; 2001 Dec; 69(4):318-27. PubMed ID: 12035293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum.
    Schmitz V; Prata RB; Barbosa MG; Mendes MA; Brandão SS; Amadeu TP; Rodrigues LS; Ferreira H; Costa Fda M; Dos Santos JB; Pacheco Fdos S; Machado Ade M; Nery JA; Hacker Mde A; Sales AM; Pinheiro RO; Sarno EN
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004955. PubMed ID: 27556927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two multidrug fixed-dosage treatment regimens with multibacillary leprosy patients.
    Gallo ME; Alvim MF; Nery JA; Albuquerque EC; Sarno EN
    Indian J Lepr; 1996; 68(3):235-45. PubMed ID: 8889609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum.
    Rea TH; Sieling PA
    Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):316-27. PubMed ID: 9934358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of late lepra reaction among multibacillary leprosy patients after MDT.
    Vijayakumaran P; Manimozhi N; Jesudasan K
    Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):18-22. PubMed ID: 7730714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does clofazimine prevent erythema nodosum leprosum (ENL) in leprosy? A retrospective study, comparing the experience of multibacillary patients receiving either 12 or 24 months WHO-MDT.
    Balagon M; Saunderson PR; Gelber RH
    Lepr Rev; 2011 Sep; 82(3):213-21. PubMed ID: 22125929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of three-year multidrug therapy in multibacillary leprosy patients.
    Li W; Ye G; Yang Z; Tao M; Luo J; Wang C; Ji F
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(1):37-40. PubMed ID: 2371263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients: a five-year report.
    Thomas A; Balakrishnan A; Nagarajan M; Prabhakar R; Tripathy SP; Christian M; Somasundaram PR
    Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):273-80. PubMed ID: 2198314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide levels in patients with erythema nodosum leprosum.
    Vieira JL; Valente Mdo S
    Ther Drug Monit; 2009 Oct; 31(5):602-3. PubMed ID: 19704404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M; Berhe D
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of thalidomide in the management of erythema nodosum leprosum.
    Walker SL; Waters MF; Lockwood DN
    Lepr Rev; 2007 Sep; 78(3):197-215. PubMed ID: 18035771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
    Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
    Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapses during long-term follow up with drug-susceptible M. leprae among multibacillary leprosy patients treated with multidrug therapy regimens; case reports.
    Thomas A; Hari L; Nagarajan M; Prabhakar R
    Int J Lepr Other Mycobact Dis; 1995 Sep; 63(3):391-4. PubMed ID: 7594922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.